PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Commentary

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Kidney International

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/SJ.KI.5000209
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Utility of endogenous creatinine clearance as a measure of renal function in mice.

  2004cited by this paper
• PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats

  2004cited by this paper
• Peroxisome Proliferator-Activated Receptor &ggr;: Implications for Cardiovascular Disease

  2004cited by this paper
• Insulin and insulin resistance: impact on blood pressure and cardiovascular disease.

  2004cited by this paper
• PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.

  2004cited by this paper
• A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury.

  2004cited by this paper
• Differential Influences of Peroxisome Proliferator–Activated Receptorsγ and -α on Food Intake and Energy Homeostasis

  2003cited by this paper
• Diabetic kidney disease in the db/db mouse.

  2003cited by this paper
• Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.

  2003cited by this paper
• Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

  2003cited by this paper
• Resistance to glomerulosclerosis in B6 mice disappears after menopause.

  2003cited by this paper
• Peroxisome Proliferator-Activated Receptor (PPAR)-α Activation Prevents Diabetes in OLETF Rats: Comparison With PPAR-γ Activation

  2003cited by this paper
• Renal Injury in Apolipoprotein E–Deficient Mice

  2002cited by this paper
• Peroxisome proliferator-activated receptors and the control of inflammation.

  2002cited by this paper
• Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPARγ activation

  2002cited by this paper
• Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.

  2001cited by this paper
• Insulin Resistance and Insulin Sensitizers

  2001cited by this paper
• Peroxisome proliferator-activated receptor-γ activity is associated with renal microvasculature

  2001cited by this paper
• Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X

  2000cited by this paper
• Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.

  2000cited by this paper
• Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging.

  1999cited by this paper
• Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Peroxisome proliferator activated receptor-alpha expression in human liver.

  1998cited by this paper
• Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats

  1998cited by this paper
• Five-hour fatty acid elevation increases muscle lipids and impairs glycogen synthesis in the rat.

  1998cited by this paper
• Reduction of insulin and triglycerides delays glomerulosclerosis in obese Zucker rats.

  1997cited by this paper
• PPARγ and the control of adipogenesis

  1997cited by this paper
• Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans.

  1997cited by this paper
• Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma.

  1996cited by this paper
• Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice.

  1996cited by this paper
• Adipogenesis and obesity: rounding out the big picture.

  1996cited by this paper
• Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.

  1996cited by this paper
• Transforming growth factor-beta modulation of the alpha 1(IV) collagen gene in murine proximal tubular cells.

  1996cited by this paper
• Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.

  1995cited by this paper
• Insulin resistance and non-insulin-dependent diabetes mellitus: cellular and molecular mechanisms.

  1995cited by this paper
• Mechanisms of fatty acid-induced inhibition of glucose uptake.

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.

  1988cited by this paper
• J Am Soc Nephrol 13: 2223–2231, 2002 PPAR Agonists Amplify iNOS Expression While Inhibiting NF-�B: Implications for Mesangial Cell Activation by

  year unknowncited by this paper

• Fenofibrate targets PPARα-CPT1C axis to reverse aging by regulating lipid metabolism and mitochondrial function.

  2026cites this paper
• Sodium hexametaphosphate mitigates calcium oxalate stone formation by modulating crystallization and maintaining PPARα signaling

  2025cites this paper
• Differential Pre- and Post-Treatment Effects of Low-Dose Antidyslipidemic Drugs on Gentamicin-Induced Acute Nephrotoxicity in the Rat: A Histopathological and Biochemical Study.

  2025cites this paper
• Lipidomics study of the regulatory effects of PPARδ agonist GW501516 in plasma of db/db diabetic mice

  2025cites this paper
• The Role of Lipotoxicity in Diabetic Nephropathy: From Physiologic Mechanisms to Therapeutic Perspectives

  2025cites this paper
• The prognostic value of remnant cholesterol to adverse renal outcomes in patients with type 2 diabetes

  2025cites this paper
• Lactobacillus acidophilus KBL409 protects against kidney injury via improving mitochondrial function with chronic kidney disease

  2024cites this paper
• Lean metabolic dysfunction-associated steatotic disease is reversed by betulinic acid, a therapeutic triterpene from birch bark

  2024cites this paper
• Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes

  2024cites this paper
• The key role of altered tubule cell lipid metabolism in kidney disease development.

  2024cites this paper
• How PPAR-alpha mediated inflammation may affect the pathophysiology of chronic kidney disease

  2024cites this paper
• Exercise alleviates diabetic kidney disease through PPAR��-CPT1�� pathway-dependent fatty acid ��-oxidation

  2024cites this paper
• Augmentation of Cathepsin Isoforms in Diabetic db/db Mouse Kidneys Is Associated with an Increase in Renal MARCKS Expression and Proteolysis

  2023cites this paper
• Fenofibrate Attenuates Renal Tubular Cell Apoptosis by Up-Regulating MCAD in Diabetic Kidney Disease

  2023cites this paper
• Unraveling the Crosstalk between Lipids and NADPH Oxidases in Diabetic Kidney Disease

  2023cites this paper
• The E3 ligase Trim63 promotes podocyte injury and proteinuria by targeting PPARα to inhibit fatty acid oxidation.

  2023cites this paper
• Nuclear receptors in renal health and disease

  2022cites this paper
• The Effect of Fibrates on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis of Randomised Studies

  2022cites this paper
• The Contribution of Lipotoxicity to Diabetic Kidney Disease

  2022cites this paper
• Protective Effect of Pueraria lobate (Willd.) Ohwi root extract on Diabetic Nephropathy via metabolomics study and mitochondrial homeostasis-involved pathways

  2022cites this paper
• New Approaches to Diabetic Nephropathy from Bed to Bench

  2022cites this paper
• Dyslipidemia and Diabetes

  2022cites this paper
• Emodin Attenuated the Kidney Damage of High-Fat-Diet Mice via the Upregulation of Glucagon-Like Peptide-1 Receptor

  2021cites this paper
• Lipotoxic Proximal Tubular Injury: A Primary Event in Diabetic Kidney Disease

  2021influential citation
• Nuclear Receptors and Transcription Factors in Obesity-Related Kidney Disease.

  2021cites this paper
• Demethylbellidifolin, a potential aldose reductase inhibitor ameliorates diabetic nephropathy by regulating the polyol pathway

  2021cites this paper
• PPARα Agonist Exerts Protective Effects in Podocyte Injury via Inhibition of the ANGPTL3 Pathway.

  2021cites this paper
• Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases

  2021cites this paper
• PPAR-α Agonist Fenofibrate Prevented Diabetic Nephropathy by Inhibiting M1 Macrophages via Improving Endothelial Cell Function in db/db Mice

  2021cites this paper
• Protective Effects of Bariatric Surgery on Kidney Functions by Inhibiting Oxidative Stress Responses Through Activating PPARα in Rats With Diabetes

  2021cites this paper
• Pregnane X receptor (PXR) protects against cisplatin-induced acute kidney injury in mice.

  2020cites this paper
• Bilirubin as a Metabolic Hormone: The Physiological Relevance of Low Levels.

  2020cites this paper
• Nuclear receptors in the kidney during health and disease.

  2020cites this paper
• High-Fat Diet Induced Hedgehog Signaling Modifications during Chronic Kidney Damage

  2020cites this paper
• Relation between resistin, PPAR-γ, obesity and atherosclerosis in male albino rats

  2020cites this paper
• Rodent models of diabetic kidney disease: human translatability and preclinical validity.

  2020cites this paper
• Fenofibrate-induced renal dysfunction, yes or no?

  2020cites this paper
• Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia

  2020cites this paper
• Peroxisome Proliferator-Activated Receptors and Caloric Restriction—Common Pathways Affecting Metabolism, Health, and Longevity

  2020cites this paper
• Attenuated Lymphatic Proliferation Ameliorates Diabetic Nephropathy and High-Fat Diet-Induced Renal Lipotoxicity

  2019cites this paper
• Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR-α/VLCAD pathway

  2019cites this paper
• Mitochondrial dysfunction in diabetic kidney disease.

  2019cites this paper
• Peroxisome proliferator-activated receptor ɑ (PPARɑ)–cytochrome P450 epoxygenases-soluble epoxide hydrolase axis in ER + PR + HER2− breast cancer

  2019cites this paper
• Review of alterations in gene expression and apoptotic pathways caused in nephrotoxicity induced by cisplatin

  2019cites this paper
• Review of alterations in gene expression and apoptotic pathways caused in nephrotoxicity induced by cisplatin.

  2019cites this paper
• Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice

  2019cites this paper
• Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist

  2018cites this paper
• Agaricus bisporus supplementation reduces high-fat diet-induced body weight gain and fatty liver development

  2018cites this paper
• PPAR-α Agonist Improves Hyperglycemia-Induced Oxidative Stress in Pancreatic Cells by Potentiating Antioxidant Defense System

  2018cites this paper
• Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context

  2018cites this paper
• Carnosic acid improves diabetic nephropathy by activating Nrf2/ARE and inhibition of NF-κB pathway.

  2018cites this paper
• Ciliogenesis is reciprocally regulated by PPARA and NR1H4/FXR through controlling autophagy in vitro and in vivo

  2018cites this paper
• Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury

  2018cites this paper
• Protective role of fenofibrate in sepsis-induced acute kidney injury in BALB/c mice

  2018cites this paper
• Low molecular weight fucoidan attenuates liver injury via SIRT1/AMPK/PGC1α axis in db/db mice.

  2018cites this paper
• Selective peroxisome proliferator‐activated receptor‐&agr; modulator K‐877 regulates the expression of ATP‐binding cassette transporter A1 in pancreatic beta cells

  2018cites this paper
• Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy.

  2018cites this paper
• Crosstalk of Hyperglycemia and Dyslipidemia in Diabetic Kidney Disease

  2017cites this paper
• Glycyrrhizic Acid Prevents Diabetic Nephropathy by Activating AMPK/SIRT1/PGC-1α Signaling in db/db Mice

  2017cites this paper
• Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway.

  2017cites this paper
• Mitochondrial energetics in the kidney

  2017cites this paper
• Reduced brain UCP2 expression mediated by microRNA-503 contributes to increased stroke susceptibility in the high-salt fed stroke-prone spontaneously hypertensive rat

  2017cites this paper
• Pharmacologic Approaches to Improve Mitochondrial Function in AKI and CKD.

  2017cites this paper
• The effects of dual PPARα/γ agonism compared with ACE inhibition in the BTBRob/ob mouse model of diabetes and diabetic nephropathy

  2017cites this paper
• PPARα agonist, fenofibrate, ameliorates age-related renal injury.

  2016cites this paper
• Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation

  2016cites this paper
• Tubular atrophy in the pathogenesis of chronic kidney disease progression

  2016cites this paper
• Grape seed procyanidin B2 protects podocytes from high glucose-induced mitochondrial dysfunction and apoptosis via the AMPK-SIRT1-PGC-1α axis in vitro.

  2016cites this paper
• PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs

  2016cites this paper
• Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway

  2016influential citation
• LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort.

  2016cites this paper
• ISN Forefronts Symposium 2015: Nuclear Receptors and Diabetic Nephropathy

  2016cites this paper
• Glucagon-like peptide-1 loaded phospholipid micelles for the treatment of type 2 diabetes: improved pharmacokinetic behaviours and prolonged glucose-lowering effects

  2016cites this paper
• Peroxisome Proliferator-Activated Receptors (PPARs) in Glucose Control

  2016cites this paper
• Identification of genes and signaling pathways associated with diabetic neuropathy using a weighted correlation network analysis

  2016cites this paper
• Oligonol, a low-molecular-weight polyphenol derived from lychee fruit, attenuates gluco-lipotoxicity-mediated renal disorder in type 2 diabetic db/db mice.

  2015cites this paper
• Diabetic kidney disease

  2015cites this paper
• Resveratrol prevents renal lipotoxicity in high-fat diet-treated mouse model through regulating PPAR-α pathway

  2015cites this paper
• PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia

  2015cites this paper
• Renoprotective Effects of Fenofibrate via Modulation of LKB1/AMPK mRNA Expression and Endothelial Dysfunction in a Rat Model of Diabetic Nephropathy

  2015cites this paper
• Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?

  2015cites this paper
• Enhancing hepatic mitochondrial fatty acid oxidation stimulates eating in food-deprived mice.

  2015cites this paper
• PREVENTIVE EFFECT OF VILDAGLIPTIN AND FENOFIBRATE ON DIABETIC NEUROPATHY IN WISTAR RATS

  2014cites this paper
• Kidney Disease in Diabetes

  2014cites this paper
• Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD).

  2014cites this paper
• Fenofibrate Improves Renal Lipotoxicity through Activation of AMPK-PGC-1α in db/db Mice

  2014cites this paper
• PPARs Integrate the Mammalian Clock and Energy Metabolism

  2014cites this paper
• Effects of CP-900691, A Novel Peroxisome Proliferator-Activated Receptor α Agonist on Diabetic Nephropathy in the BTBR ob/ob mouse

  2014cites this paper
• Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats.

  2014cites this paper
• Developments in renal pharmacogenomics and applications in chronic kidney disease

  2014cites this paper
• Nuclear Hormone Receptor Expression in Mouse Kidney and Renal Cell Lines

  2014cites this paper
• An ACACB Variant Implicated in Diabetic Nephropathy Associates with Body Mass Index and Gene Expression in Obese Subjects

  2013cites this paper
• Inflammation and the pathogenesis of diabetic nephropathy.

  2013cites this paper
• Mechanisms of diabetic complications.

  2013cites this paper
• Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy.

  2013cites this paper
• Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes

  2013cites this paper
• Mammalian Tribbles Homologs at the Crossroads of Endoplasmic Reticulum Stress and Mammalian Target of Rapamycin Pathways

  2013cites this paper
• Fenofibrate Attenuated Glucose-Induced Mesangial Cells Proliferation and Extracellular Matrix Synthesis via PI3K/AKT and ERK1/2

  2013cites this paper
• Complexity of diabetic nephropathy pathogenesis and design of investigations

  2013cites this paper
• Xenobiotic receptor humanized mice and their utility

  2013cites this paper